洛铂在妇科肿瘤治疗中的研究新进展  

New progression of lobaplatin in the treatment of gynecologic cancer

作　　者：杨志敏[1] 林原[2] 陈佳艺[2] 王华英[1] 

机构地区：[1]复旦大学肿瘤医院妇科,上海200032 [2]复旦大学肿瘤医院放疗科,上海200032

出　　处：《国际肿瘤学杂志》2014年第11期848-851,共4页Journal of International Oncology

摘　　要：洛铂是第3代铂类抗肿瘤药物,已上市用于临床治疗晚期乳腺癌、小细胞肺癌和慢性粒细胞白血病.研究表明洛铂作为最新的第3代铂类抗肿瘤药物,具有水溶性好,抗瘤谱广、抗瘤活性强,与其他铂类药物无交叉耐药性及不良反应低诸多特点,已经显示出明显的优势.Lobaplatin is the third generation platinum anticancer drug,and has been listed for the clinical treatment of advanced breast cancer,small cell lung cancer and chronic myeloid leukemia.Studies have shown that lobaplatin as the latest third generation platinum anticancer drug,has good water solubility,broadspectrum anti-tumor,strong anti-tumor activity,no cross-resistance with other platinum drugs,low toxicity and many other features.Lobaplatin has shown a clear advantage.

关 键 词：洛铂 生殖器肿瘤 女(雌)性 药物疗法 

分 类 号：R737.3[医药卫生—肿瘤]